Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free AMGN Stock Alerts

Amgen (AMGN) Competitors

Amgen logo
$355.20 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$353.42 -1.78 (-0.50%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AMGN vs. GILD, MRNA, VRTX, ABBV, and AZN

Should you buy Amgen stock or one of its competitors? MarketBeat compares Amgen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amgen include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), and Astrazeneca (AZN).

How does Amgen compare to Gilead Sciences?

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Amgen has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gilead Sciences has lower revenue, but higher earnings than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B5.22$7.71B$14.3724.72
Gilead Sciences$29.44B5.30$8.51B$7.3417.11

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen20.96% 137.41% 13.28%
Gilead Sciences 30.99%48.19%18.28%

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.8%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.6%. Amgen pays out 70.1% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen currently has a consensus price target of $354.12, indicating a potential downside of 0.31%. Gilead Sciences has a consensus price target of $156.93, indicating a potential upside of 24.95%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.48
Gilead Sciences
0 Sell rating(s)
4 Hold rating(s)
25 Buy rating(s)
0 Strong Buy rating(s)
2.86

In the previous week, Gilead Sciences had 17 more articles in the media than Amgen. MarketBeat recorded 71 mentions for Gilead Sciences and 54 mentions for Amgen. Gilead Sciences' average media sentiment score of 1.31 beat Amgen's score of 1.28 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
42 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Gilead Sciences
54 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Gilead Sciences beats Amgen on 11 of the 20 factors compared between the two stocks.

How does Amgen compare to Moderna?

Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B5.22$7.71B$14.3724.72
Moderna$1.94B10.19-$2.82B-$8.15N/A

In the previous week, Amgen had 35 more articles in the media than Moderna. MarketBeat recorded 54 mentions for Amgen and 19 mentions for Moderna. Amgen's average media sentiment score of 1.28 beat Moderna's score of 0.57 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
42 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
11 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Amgen has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Amgen currently has a consensus price target of $354.12, indicating a potential downside of 0.31%. Moderna has a consensus price target of $36.60, indicating a potential downside of 26.67%. Given Amgen's stronger consensus rating and higher possible upside, analysts clearly believe Amgen is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.48
Moderna
5 Sell rating(s)
11 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.83

Amgen has a net margin of 20.96% compared to Moderna's net margin of -143.55%. Amgen's return on equity of 137.41% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen20.96% 137.41% 13.28%
Moderna -143.55%-26.64%-19.32%

Summary

Amgen beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Amgen compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Vertex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vertex Pharmaceuticals35.51% 23.86% 17.13%
Amgen 20.96%137.41%13.28%

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Amgen had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 54 mentions for Amgen and 43 mentions for Vertex Pharmaceuticals. Amgen's average media sentiment score of 1.28 beat Vertex Pharmaceuticals' score of 1.24 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vertex Pharmaceuticals
32 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Amgen
42 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Amgen has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$12.00B9.41$3.95B$16.8626.39
Amgen$36.75B5.22$7.71B$14.3724.72

Vertex Pharmaceuticals currently has a consensus price target of $555.91, indicating a potential upside of 24.95%. Amgen has a consensus price target of $354.12, indicating a potential downside of 0.31%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vertex Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
22 Buy rating(s)
0 Strong Buy rating(s)
2.88
Amgen
2 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.48

Summary

Vertex Pharmaceuticals beats Amgen on 9 of the 17 factors compared between the two stocks.

How does Amgen compare to AbbVie?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Amgen presently has a consensus price target of $354.12, indicating a potential downside of 0.31%. AbbVie has a consensus price target of $253.43, indicating a potential upside of 11.38%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.48
AbbVie
0 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.88

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.8%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.0%. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen20.96% 137.41% 13.28%
AbbVie 5.79%-576.45%13.39%

Amgen has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

In the previous week, AbbVie had 26 more articles in the media than Amgen. MarketBeat recorded 80 mentions for AbbVie and 54 mentions for Amgen. Amgen's average media sentiment score of 1.28 beat AbbVie's score of 1.16 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
42 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
55 Very Positive mention(s)
9 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Positive

76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B5.22$7.71B$14.3724.72
AbbVie$61.16B6.57$4.23B$2.03112.09

Summary

AbbVie beats Amgen on 11 of the 20 factors compared between the two stocks.

How does Amgen compare to Astrazeneca?

Amgen (NASDAQ:AMGN) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Amgen presently has a consensus target price of $354.12, suggesting a potential downside of 0.31%. Astrazeneca has a consensus target price of $205.33, suggesting a potential upside of 14.85%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.48
Astrazeneca
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.85

Amgen has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

76.5% of Amgen shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen20.96% 137.41% 13.28%
Astrazeneca 17.19%30.86%12.68%

In the previous week, Amgen had 41 more articles in the media than Astrazeneca. MarketBeat recorded 54 mentions for Amgen and 13 mentions for Astrazeneca. Amgen's average media sentiment score of 1.28 beat Astrazeneca's score of 0.55 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
42 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Astrazeneca
3 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B5.22$7.71B$14.3724.72
Astrazeneca$60.44B4.59$10.23B$6.6626.85

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Amgen pays out 70.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Astrazeneca on 14 of the 20 factors compared between the two stocks.

Get Amgen News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMGN vs. The Competition

Export
MetricAmgenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$191.70B$3.40B$6.74B$12.07B
Dividend Yield2.84%2.25%2.67%5.67%
P/E Ratio24.7219.8224.2124.42
Price / Sales5.22305.69512.04109.94
Price / Cash10.5153.6127.4837.92
Price / Book22.098.3210.666.83
Net Income$7.71B$23.94M$3.57B$337.67M
7 Day Performance2.76%1.84%0.58%1.17%
1 Month Performance8.85%-0.04%1.54%3.16%
1 Year Performance20.32%44.82%25.40%30.58%

Amgen Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
3.8009 of 5 stars		$355.20
flat		$354.12
-0.3%		+20.3%$191.70B$36.75B24.7231,500
GILD
Gilead Sciences
4.9225 of 5 stars		$129.16
+1.2%		$156.93
+21.5%		+14.2%$160.36B$29.44B17.6017,000
MRNA
Moderna
1.312 of 5 stars		$47.10
+3.2%		$35.73
-24.1%		+87.1%$18.69B$1.94BN/A4,700
VRTX
Vertex Pharmaceuticals
4.6366 of 5 stars		$426.77
+0.4%		$555.91
+30.3%		-2.3%$108.31B$12.00B25.316,400
ABBV
AbbVie
4.4783 of 5 stars		$218.85
+1.6%		$253.43
+15.8%		+19.3%$386.66B$61.16B107.8157,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AMGN) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel